Serum CCL21 as a Potential Biomarker for Cognitive Impairment in Spinal Cord Injury

• Published in: BioMed research international 2020, Vol.2020 (2020), p.1-5
• Main Authors: Shi, Bin, Zhang, Qian, Hou, Guangjian, Cao, Shengnan, Liang, Liangke, Chen, Yuanzhen, Ma, Hong
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age; Aged; Aged, 80 and over; Analysis; Biological markers; Biomarkers; Biomarkers - blood; Blood pressure; Body mass index; Care and treatment; Case-Control Studies; CCL21 protein; Chemokine CCL21 - blood; Chemokines; Cholesterol; Cognition disorders; Cognitive ability; Cognitive Dysfunction - blood; Cognitive Dysfunction - complications; Correlation analysis; Cytokines; Dementia; Demographics; Demography; Diagnosis; Enzyme-Linked Immunosorbent Assay; Fasting; Female; Gender; Glucose; Humans; Impairment; Ligands; Lipoproteins; Low density lipoprotein; Low density lipoproteins; Male; Mental Status and Dementia Tests; Middle Aged; Multivariate Analysis; Pain; Patients; Prevention; Risk analysis; Risk Factors; Spinal cord injuries; Spinal Cord Injuries - blood; Spinal Cord Injuries - complications; Statistical analysis; Triglycerides; Young Adult
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2020/6692802

Objective. Cognitive impairment is considered to be an important complication of spinal cord injury (SCI), but its underlying mechanism remains unclear. The purpose of this study is to explore whether serum CCL21 can be used as a potential biomarker of cognitive impairment in SCI. Methods. In Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, hospitalized or treated acute SCI patients were included in the study as the SCI group (SCI). At the same time, a normal control group (NC) matching the age and sex of the SCI group was recruited in the outpatient clinic. Once the two groups were enrolled, their demographics and clinical characteristics were collected immediately. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum CCL21 levels within 24 hours of admission. Three months later, the Montreal Cognitive Assessment (MoCA) was used to test the cognitive function of the population. Results. A total of 84 SCI patients and 49 NC populations were eligible for inclusion in the study. There was no significant statistical difference in the demographics and clinical characteristics (age, gender, BMI, TG, LDL-C, FBG, SBP, and DBP) between the two groups (p>0.05). Compared with the NC group, the SCI group had a higher serum CCL21 level (p